FDA-cleared profile

SIGNA Premier

GE Medical Systems, LLC · MRI · FDA-cleared (510(k))

Authorized purpose: SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K183231 adds AIRx, a deep-learning pre-scan feature that automates and standardizes connected brain-examination prescription steps, while resulting images and spectra remain interpreted by a trained physician.

Clinical role
AIRx operates before image acquisition in brain MRI workflow, using deep learning to automate and standardize connected examination prescription and setup steps. The wider SIGNA Premier platform then acquires and reconstructs the prescribed examination for physician review.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: AIRx is a pre-scan algorithm, and the resulting images and/or spectra must be interpreted by a trained physician.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K183231 adds AIRx, a deep-learning pre-scan feature that automates and standardizes connected brain-examination prescription steps, while resulting images and spectra remain interpreted by a trained physician.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: Data used by the AIRx pre-scan algorithm to automate and standardize connected steps required for an MRI examination of the brain.
  • Who uses it?Intended users: Trained physicians for interpretation of the resulting images and/or spectra.
  • What does the software produce?Output: Automated and standardized connected steps required for an MRI examination of the brain, followed by the SIGNA Premier system's diagnostic MRI images and/or spectra.
  • What is its most important limitation?Key limitation: AIRx is a pre-scan algorithm, and the resulting images and/or spectra must be interpreted by a trained physician.

Clinical takeaway. Clinical role: SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K183231 adds AIRx, a deep-learning pre-scan feature that automates and standardizes connected brain-examination prescription steps, while resulting images and spectra remain interpreted by a trained physician.

Evidence takeaway. Evidence from the reviewed source record: Exact-submission evidence is limited to manufacturer verification, validation, simulated-use testing, and internal scans summarized by FDA. The review did not identify an independent peer-reviewed study or registered trial that could be confidently mapped to the K183231 AIRx implementation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K183231 adds AIRx, a deep-learning pre-scan feature that automates and standardizes connected brain-examination prescription steps, while resulting images and spectra remain interpreted by a trained physician.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
AIRx operates before image acquisition in brain MRI workflow, using deep learning to automate and standardize connected examination prescription and setup steps. The wider SIGNA Premier platform then acquires and reconstructs the prescribed examination for physician review.
  • Exact FDA submission
  • Checked 2026-09-02
Required input
Data used by the AIRx pre-scan algorithm to automate and standardize connected steps required for an MRI examination of the brain.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states this AIRx function but does not establish the dossier's patient-setup, localizer, coil, and parameter list.

Output and clinician action
Automated and standardized connected steps required for an MRI examination of the brain, followed by the SIGNA Premier system's diagnostic MRI images and/or spectra.
  • Exact FDA submission
  • Checked 2026-09-19

The packet states AIRx automates and standardizes connected examination steps and separately states the SIGNA Premier image/spectra outputs; it does not state technologist review or the dossier's full output list.

Care setting
Professional MRI facilities equipped for a fixed 3.0T whole-body scanner, MR safety controls, patient screening, protocol governance, image interpretation, and ongoing service and quality assurance.
  • Exact FDA submission
  • Checked 2026-09-02
Intended users
Trained physicians for interpretation of the resulting images and/or spectra.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet names the trained physician as interpreter and does not establish the dossier's trained-imaging-personnel role.

Limitations
AIRx is a pre-scan algorithm, and the resulting images and/or spectra must be interpreted by a trained physician.
  • Exact FDA submission
  • Checked 2026-09-19

This is the exact pre-scan and interpretation boundary in the packet; the broader unsupported performance and patient-outcome claims are removed.

Evidence summary
Exact-submission evidence is limited to manufacturer verification, validation, simulated-use testing, and internal scans summarized by FDA. The review did not identify an independent peer-reviewed study or registered trial that could be confidently mapped to the K183231 AIRx implementation.
  • Exact FDA submission
  • Checked 2026-09-02

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact-submission evidence is limited to manufacturer verification, validation, simulated-use testing, and internal scans summarized by FDA. The review did not identify an independent peer-reviewed study or registered trial that could be confidently mapped to the K183231 AIRx implementation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K183231 AIRx manufacturer verification and validation

  • DesignManufacturer nonclinical verification and validation with risk management, design review, system integration, performance, simulated-use testing, and internal scans
  • PopulationSIGNA Premier engineering and simulated-use tests plus internal brain MRI scans used to assess prescription productivity and consistency; public sample size not reported
  • Scopeexact submission
  • Tested versionSIGNA Premier with AIRx cleared in K183231
  • IndependenceSponsor or vendor study

K183231

The public FDA summary reports that testing passed but does not provide a reader count, independent clinical site, diagnostic-accuracy endpoint, confidence interval, or patient-outcomes analysis.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
FDA recall Z-1767-2026 includes SIGNA Premier systems that may contain ferrous steel fittings at the rear of the magnet instead of non-ferrous brass fittings, creating a personnel-injury risk if the rear is serviced while the magnet is ramped. FDA lists the recall as open and classified. FDA recall Z-2304-2025 includes SIGNA Premier systems for which planned maintenance may not have checked patient-table caster-lock function, allowing an undocked table to move during patient transfer. FDA lists the recall as open and classified. FDA recall Z-2462-2024 includes SIGNA Premier software RX27.0-RX27.3, RX28.0, RX29.0-RX29.2, MR30.0, and MR30.1. Under specified Low SAR and 2D T2 FLAIR settings, predicted B1+RMS can exceed the prescribed limit and overheat an MR-conditional implant. FDA lists the recall as open and classified. FDA recall Z-1430-2022 affects SIGNA Premier model 5748519 because rare gradient-coil conditions could produce elevated acoustic noise and prolonged exposure could lead to hearing loss. FDA lists the recall as open and classified. FDA recall Z-0590-2022 includes the superconducting magnet used in SIGNA Premier systems because the cryogen ventilation system may not meet venting requirements. FDA lists the recall as open and classified. FDA recall Z-0132-2022 affected SIGNA Premier because some slices could be missing under certain conditions, creating a gap in anatomy in three-dimensional volume images. FDA lists the recall as terminated. FDA recall Z-2052-2021 affected SIGNA Premier because a user intending to select Save RX could inadvertently select Patient Orientation before the initial three-plane localizer, potentially producing incorrectly annotated or flipped images. FDA lists the recall as open and classified.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-1767-2026

Open, Classified

2026-04-02

Native K183231 and SIGNA Premier match. This is a system hardware and service-access issue, not an AIRx algorithm defect; verify affected-unit and correction status with GE before rear-magnet service.

recall: Z-2304-2025

Open, Classified

2025-08-13

Native K183231 and SIGNA Premier match. This is a patient-table maintenance issue, not an AIRx defect; verify caster locks before transfer and confirm GE inspection or correction status.

recall: Z-2462-2024

Open, Classified

2024-08-02

Native K183231 and SIGNA Premier match, but the clearance summary does not establish the installed software build. This is an MR sequence and safety-control issue rather than evidence of an AIRx defect; verify software, optimized-FLAIR configuration, workaround, and correction status.

recall: Z-1430-2022

Open, Classified

2022-06-24

Native K183231 and exact SIGNA Premier model match. This is a gradient-coil acoustic-safety issue, not an AIRx algorithm defect; verify affected-unit status, the operator-manual addendum, and use of hearing protection rated at least 33 dB NRR.

recall: Z-0590-2022

Open, Classified

2021-12-23

Native K183231 and SIGNA Premier component match. This is a facility, magnet, and quench-safety issue, not an AIRx defect; verify ventilation inspection, evacuation procedures, and correction status.

recall: Z-0132-2022

Terminated

2021-10-16

Native K183231 and SIGNA Premier match. This is a reconstructed-volume completeness issue; the FDA record does not identify AIRx as the cause. Confirm the correction is installed and preserve image-completeness review controls.

recall: Z-2052-2021

Open, Classified

2021-07-12

Native K183231 and SIGNA Premier match. This is a user-interface and acquisition-workflow issue, not an AIRx algorithm-performance finding; verify actual versus prescribed orientation before scanning and confirm correction status.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
No public purchase price for the K183231 SIGNA Premier system or AIRx option was found. GE lists a separate 3.5-day advanced SIGNA Premier service course at $15,500 tuition only, $16,100 with lodging, or $17,600 with lodging and airfare; these amounts are implementation-cost benchmarks, not scanner, software, maintenance, or clinical-training prices.
  • Product family
  • Checked 2026-09-02

Pricing context

These observations are not an exact-product procurement quotation. They are family, vendor, patient-charge, reimbursement, model, or unscoped records and are not comparable across dates, bundles, currencies, or units.

USD 15500

Price observation, scope not stated · one-student, 3.5-day advanced service-training course; tuition-only through tuition, lodging, and airfare options · United States

Observed 2026-09-02

Public GE service-training list prices for biomedical engineers. This is not a scanner price, AIRx license price, implementation quote, clinical-user course, maintenance agreement, or total-cost estimate.

Reimbursement

Reimbursement
CMS NCD 220.2 addresses coverage of medically necessary MRI and MRA services performed on FDA-authorized equipment within its labeling; it does not establish a separate payment for SIGNA Premier, AIRx, or automated brain prescription. Coverage, coding, payment, and prior-authorization analysis remains examination-, payer-, site-, and patient-specific.
  • Service-level, not product-specific
  • Checked 2026-09-02

No product-specific code

No separate named-product payment identified in CMS NCD 220.2

Medicare · United States · Effective 2018-04-10

The NCD provides MRI and MRA coverage context and does not assign payment to AIRx. Verify the ordered examination, medical necessity, current code set, site of service, payer contract, and local coverage rules.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Data used by the AIRx pre-scan algorithm to automate and standardize connected steps required for an MRI examination of the brain.

    Scope: Exact FDA submission. The exact device description states this AIRx function but does not establish the dossier's patient-setup, localizer, coil, and parameter list.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K183231: SIGNA Premier

  2. Routing

    Source context, not route validation: The FDA summary describes SIGNA Premier as DICOM conformant. GE publishes software-specific DICOM conformance statements for the SIGNA Premier family, including RX27.0, but interoperability still depends on the installed software, configured services, PACS and RIS endpoints, and local validation.

    Scope: Product family. Obtain the conformance statement for the installed software build and test worklist, patient demographics, image and presentation-state transfer, routing, failure recovery, and archive behavior end to end.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-02 · FDA K183231: SIGNA Premier · SIGNA Premier and SIGNA Architect RX27.0 DICOM conformance statement

  3. AI processing

    Source context, not route validation: Fixed on-premises 3.0T whole-body MRI system with a 70 cm bore. AIRx is embedded in the SIGNA Premier acquisition workflow rather than deployed as a separate cloud triage or diagnostic service.

    Scope: Exact FDA submission. A site still needs scanner-room planning, shielding and power review, MR safety zoning, coil and protocol configuration, PACS and RIS integration, acceptance testing, service coverage, and downtime procedures.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-02 · FDA K183231: SIGNA Premier

  4. Returned objects

    Source context, not route validation: Automated and standardized connected steps required for an MRI examination of the brain, followed by the SIGNA Premier system's diagnostic MRI images and/or spectra.

    Scope: Exact FDA submission. The packet states AIRx automates and standardizes connected examination steps and separately states the SIGNA Premier image/spectra outputs; it does not state technologist review or the dossier's full output list.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K183231: SIGNA Premier

  5. Viewer/worklist/report

    Unresolved route: Automated and standardized connected steps required for an MRI examination of the brain, followed by the SIGNA Premier system's diagnostic MRI images and/or spectra.

    Scope: Exact FDA submission. The packet states AIRx automates and standardizes connected examination steps and separately states the SIGNA Premier image/spectra outputs; it does not state technologist review or the dossier's full output list.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K183231: SIGNA Premier

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Fixed on-premises 3.0T whole-body MRI system with a 70 cm bore. AIRx is embedded in the SIGNA Premier acquisition workflow rather than deployed as a separate cloud triage or diagnostic service.
  • Exact FDA submission
  • Checked 2026-09-02

A site still needs scanner-room planning, shielding and power review, MR safety zoning, coil and protocol configuration, PACS and RIS integration, acceptance testing, service coverage, and downtime procedures.

Integration
The FDA summary describes SIGNA Premier as DICOM conformant. GE publishes software-specific DICOM conformance statements for the SIGNA Premier family, including RX27.0, but interoperability still depends on the installed software, configured services, PACS and RIS endpoints, and local validation.
  • Product family
  • Checked 2026-09-02

Obtain the conformance statement for the installed software build and test worklist, patient demographics, image and presentation-state transfer, routing, failure recovery, and archive behavior end to end.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
The FDA-cleared workflow requires trained personnel and trained-physician interpretation. GE separately offers a 3.5-day classroom and lab course for biomedical engineers servicing SIGNA Premier systems; this is service training, not evidence of the clinical-user training package supplied with K183231.
  • Product family
  • Checked 2026-09-02

Require role-specific operator, radiologist, physicist, MR safety, service, protocol-approval, and fallback training and document competency before clinical use.

AIRx brain prescription

AIRx automates and standardizes connected pre-scan steps used to prescribe and set up brain MRI examinations on SIGNA Premier.

exact submission · checked 2026-09-02

Validate landmarking, plane prescription, edge cases, technologist review, manual override, fallback, and protocol-change controls across the local brain protocol catalog.

Whole-body 3T MRI platform

The cleared system is a superconducting 3.0T whole-body scanner with a 70 cm bore and supports multiplanar, dynamic, parametric, and spectroscopic outputs across multiple anatomies.

exact submission · checked 2026-09-02

Map purchased coils, pulse sequences, accessories, software options, and applications to the installed configuration; the clearance does not establish that every option is licensed at every site.

DICOM connectivity

FDA describes the system as DICOM conformant, and GE publishes software-specific SIGNA Premier conformance statements including RX27.0.

product family · checked 2026-09-02

A conformance statement is a planning input, not proof of interoperability. Execute interface, routing, metadata, display, storage-commitment, and recovery tests against each local system.

Current product-family context

GE continues to market SIGNA Premier as a 3T wide-bore platform and currently presents AIRx and AIR Recon DL within the family, but later hardware, software, and feature claims may not apply to the K183231 configuration.

product family · checked 2026-09-02

Require a configuration matrix connecting each quoted feature and service commitment to the exact scanner serial number, software build, license, and FDA clearance.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K183231
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-01-18
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
14Source classes checked
12Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 12 PubMed and 6 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 12 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 7 FDA recall candidates were manually reviewed: 7 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 7 postmarket candidate records; 7 have been reviewed (7 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, peer reviewed publication, trial registry, vendor product page, vendor interoperability, vendor pricing observation, reimbursement policy, fda device recall, fda decision summary packet, literature index, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Monitoring: Not publicly available - checked 2026-09-02 - Exact product version

    No public exact-version operational-monitoring specification was established. A local program should track AIRx prescription overrides and errors, repeat and aborted scans, protocol drift, image-quality complaints, DICOM failures, downtime, service actions, hearing-protection and MR safety controls, software versions, and open recall corrections.

17 sources - 3 history items

Source ledger

  1. FDA K183231: SIGNA Premier

    U.S. Food and Drug Administration - Published 2019-01-18 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, evidenceSummary, intendedUsers, input, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-1767-2026: SIGNA Premier systems

    U.S. Food and Drug Administration - Published 2026-04-02 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-2304-2025: GE SIGNA Premier, Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2025-08-13 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. FDA recall Z-2462-2024: SIGNA Premier, with affected software versions: RX27.0 to RX27.3, RX28.0, RX29.0 to RX29.2, MR30.0, MR30.1; Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2024-08-02 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  6. FDA recall Z-1430-2022: SIGNA Premier magnetic resonance scanner, model 5748519.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  7. FDA recall Z-0590-2022: GE Healthcare MR superconducting magnets, a component of GE Healthcare SIGNA Premier System, nuclear magnetic resonance imaging system.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  8. FDA recall Z-0132-2022: SIGNA Premier nuclear magnetic resonance imaging system

    U.S. Food and Drug Administration - Published 2021-10-16 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  9. FDA recall Z-2052-2021: SIGNA Premier - Product Usage: is a whole body magnetic resonance scanner designed to support high resolution, high signal-to-noise ratio, and short scan times.

    U.S. Food and Drug Administration - Published 2021-07-12 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  10. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  11. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  12. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  13. SIGNA Premier 3T wide-bore scanner

    GE HealthCare - Accessed 2026-09-02

    Scope: productFamily, implementationCapabilities, currentCommercialContext

  14. SIGNA Premier and SIGNA Architect RX27.0 DICOM conformance statement

    GE HealthCare - Accessed 2026-09-02

    Scope: integration, implementationCapabilities, softwareVersion

  15. MR Advanced 3.0T SIGNA Premier Service Training

    GE HealthCare - Accessed 2026-09-02

    Scope: training, pricing, economicsObservation, implementationCapabilities

  16. National Coverage Determination 220.2: Magnetic Resonance Imaging

    Centers for Medicare & Medicaid Services - Published 2018-04-10 - Accessed 2026-09-02

    Scope: reimbursement, mriCoverageContext

  17. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K183231 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history